Standardization of Thrombaptanib Drug Substance for Residual Organic Solvents


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Results from experiments conducted for the parameter Residual Organic Solvents during the course of developing a draft regulation for the drug substance of the innovative pharmacological agent thrombaptanib are reported. The structure of the compound is given. Its pharmacological action is described. A list of potential residual organic solvents was compiled by analyzing the synthetic scheme and manufacturing technology. A separate part of the work describes in detail a developed GC-MS procedure for determining residual organic solvents. Validation results of the procedure for Specificity, Linearity, Accuracy, Precision, and Reproducibility are presented. The validation protocol for the procedure at the time of the studies followed domestic guides for validation that were written based on existing international documents because there was no existing GPM for validation in the current edition of the SP RF. A test sample of thrombaptanib was analyzed using the developed procedure for Residual Organic Solvents. The developed procedure was included in the Residual Organic Solvents section of the draft regulation.

About the authors

A. E. Petukhov

I. M. Sechenov First Moscow State Medical University; Moscow Narcology Research and Practice Center, Moscow City Department of Health

Email: a-l-e-x4@yandex.ru
Russian Federation, Moscow, 119991; Moscow, 103390

E. A. Petrykina

I. M. Sechenov First Moscow State Medical University

Email: a-l-e-x4@yandex.ru
Russian Federation, Moscow, 119991

O. I. Tereshkina

I. M. Sechenov First Moscow State Medical University

Email: a-l-e-x4@yandex.ru
Russian Federation, Moscow, 119991

G. V. Ramenskaya

I. M. Sechenov First Moscow State Medical University

Email: a-l-e-x4@yandex.ru
Russian Federation, Moscow, 119991

O. M. Antipova

APTO-FARM Company

Author for correspondence.
Email: a-l-e-x4@yandex.ru
Russian Federation, Moscow, 115230

A. D. Turashev

APTO-FARM Company

Email: a-l-e-x4@yandex.ru
Russian Federation, Moscow, 115230

E. G. Zav’yalova

APTO-FARM Company; Department of Chemistry, M. V. Lomonosov Moscow State University

Email: a-l-e-x4@yandex.ru
Russian Federation, Moscow, 115230; Moscow, 119991

A. V. Golovin

APTO-FARM Company; Department of Bioengineering and Bioinformatics, M. V. Lomonosov Moscow State University

Email: a-l-e-x4@yandex.ru
Russian Federation, Moscow, 115230; Moscow, 119991

G. V. Pavlova

APTO-FARM Company; Institute of Gene Biology, Russian Academy of Sciences

Email: a-l-e-x4@yandex.ru
Russian Federation, Moscow, 115230; Moscow, 119334

A. M. Kopylov

APTO-FARM Company; Department of Chemistry, M. V. Lomonosov Moscow State University

Email: a-l-e-x4@yandex.ru
Russian Federation, Moscow, 115230; Moscow, 119991


Copyright (c) 2018 Springer Science+Business Media, LLC, part of Springer Nature

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies